Pulmatrix, Inc (PULM) fair value: what the stock is really worth
As of Nov 19, 2026: fair value (intrinsic value) of Pulmatrix, Inc stock $0.59, price $1.42, that is 58.5% below the price, quality 49 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Pulmatrix, Inc
PULM · USFar too expensive (fair value 59% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 19, 2026.
How to read this chart
60‑month range $1.19 – $20.00 · fair‑value band $0.44 – $0.73 · the $1.42 price screens above the $0.59 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 19, 2026.
Every Wednesday you see whether Pulmatrix is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States.
Show moreShow less
The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine.
It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.
Stock analysis
Pulmatrix, Inc (PULM) currently trades at $1.42, while our estimate is $0.59, 59% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $0.44 (bear) to $0.73 (bull), the price of $1.42 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Pulmatrix, Inc reported revenue of $0 in FY2025 versus $5.2M in FY2021. Reported net income was −$5.2M in FY2025.
Key figures
Market cap $5.2M Micro · EPS (TTM) $-1.20 · Return on equity −143% · Return on assets (EBIT) −69.4% (5-year average) · Revenue (TTM) $3.0K · Free cash flow −$5.4M · Net cash $4.1M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).
What moves the price
The share trades about 70% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −59%, PULM screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare Pulmatrix, Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 851 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Quality Score by industry
- Return on equity by industry
- PEG screener for stocks with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $923.34 | $1,275.02 | +38% | vs PULM |
| Vertex Pharmaceuticals Incorporated VRTX | $520.66 | $587.62 | +13% | vs PULM |
| Samsung Biologics Co 207940 | ₩1,375,000 | ₩1,512,500 | +10% | vs PULM |
| argenx SE ARGX | $942.04 | $908.40 | −4% | vs PULM |
| CSL Limited CSL | A$197.29 | A$188.80 | −4% | vs PULM |
| BeOne Medicines AG 6160 | HK$242.60 | HK$152.92 | −37% | vs PULM |
| Moderna, Inc MRNA | $199.33 | $122.98 | −38% | vs PULM |
| Revolution Medicines, Inc RVMD | $159.43 | $83.12 | −48% | vs PULM |
| Celltrion, Inc 068270 | ₩215,000 | ₩74,574 | −65% | vs PULM |
| Royalty Pharma plc RPRX | $67.72 | $19.01 | −72% | vs PULM |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Pulmatrix, Inc (PULM) overvalued or undervalued?
What is the fair value of PULM?
What is the quality score of PULM?
What is the price target for Pulmatrix, Inc (PULM)?
What is the Pulmatrix, Inc stock forecast for 2026?
What is the revenue of Pulmatrix, Inc (PULM)?
What is the intrinsic value of Pulmatrix, Inc (PULM)?
Is Pulmatrix, Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of PULM?
How much is Pulmatrix, Inc worth?
What do the bullish and bearish scenarios say about PULM?
How solid is the balance sheet of Pulmatrix, Inc (PULM)?
How far is PULM from its 52-week high?
Which stocks are comparable to Pulmatrix, Inc?
Is Pulmatrix, Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Pulmatrix, Inc (PULM)?
What should I pay attention to with Pulmatrix, Inc right now?
Key figures of Pulmatrix, Inc
How large is the market capitalisation of Pulmatrix, Inc (PULM)?
What are the earnings per share of Pulmatrix, Inc (PULM)?
What is the return on equity of Pulmatrix, Inc (PULM)?
What is the EBIT return on assets of Pulmatrix, Inc (PULM)?
How much free cash flow does Pulmatrix, Inc (PULM) generate?
How much net cash does Pulmatrix, Inc (PULM) hold?
Watch Pulmatrix, Inc in the live analysis
One click puts Pulmatrix, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.